NASDAQ · PAVM

PAVmed Inc.

$4.74 +$0.20 (+4.41%) 1D Market open

Key Metrics

$32.50M
Market cap
P/E · TTM
$85.00K
Revenue · TTM
−$18.63M
Net income
EPS · TTM $-10.66
Dividend yield
Free cash flow −$6.29M
Beta · 1Y 0.98
EBITDA · TTM −$22.07M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 26
    The stock moved +16.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 26
  • Jun 25
    From its Feb 10 high, the share price fell 60%.

    Peak close $10.96 on Feb 10; trough close $4.35 on Jun 25. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -60%
  • Feb 2
    The stock moved +20.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 2

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$32.50M
Enterprise value
Shares outstanding7.2M
52-wk range$0.21 – $28.44
Avg volume · 20D167.1K
Net cash
Book value / share$22.63
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About PAVmed Inc.
IPO dateApr 28, 2016
Employees41

PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S382.38
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -26,065.9%
Net -21,914.1%
FCF -7,402.4%
ROE / ROIC -100.6% · —

Financial Health

Current ratio2.02
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$3.75M

Cash Flow · TTM

Operating CF −$6.25M
Capex −$47.00K
Free cash flow −$6.29M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

-8.5
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings